share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease

獨家報道:SAB BioTreateutics告訴Benzinga SAB重點介紹了用於季節性和大流行性流感的SAB-176和用於新冠肺炎的SAB-185的數據,顯示出對與呼吸系統疾病相關的高度變異病毒的廣泛療效
Benzinga Real-time News ·  2022/11/03 08:41

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease

獨家報道:SAB BioTreateutics告訴Benzinga SAB重點介紹了用於季節性和大流行性流感的SAB-176和用於新冠肺炎的SAB-185的數據,顯示出對與呼吸系統疾病相關的高度變異病毒的廣泛療效

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論